Quantification of endostar in rat plasma by LC-MS/MS and its application in a pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 70, Issue , 2012, Pages 505-511

  Li, Ying Chun ^a   Liang, Yan ^a   Tang, Zhi Yuan ^a   Xiao, Ya Nan ^a   Hao, Hai Ping ^a   Wang, Guang Ji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absolute quantification; Endostar; LC MS MS; Pharmacokinetic

Indexed keywords

NICKEL; RECOMBINANT ENDOSTATIN; SEPHAROSE; SYNTHETIC PEPTIDE; THREONYLGLUTAMYLALANYLPROLYLSERYLALANYLTHREONYLGLYCYLGLUTAMINYLALANYLSERYLSERYLLEUCYLLEUCYLGLYCYLGLYCYLARGININE; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANGIOGENESIS INHIBITORS; ANIMALS; CALIBRATION; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; ENDOSTATINS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIMIT OF DETECTION; LINEAR MODELS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEPHAROSE; TANDEM MASS SPECTROMETRY;

EID: 84866258918     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.07.017     Document Type: Article

References (17)

1. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
2. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 2006, 312:594-607.
3. Zheng M.J. Endostatin derivative angiogenesis inhibitors. Chin. Med. J. 2009, 122:1947-1951.
4. Zhou Z.T., Zhou F.X., Wei Q., Zou L.Y., Qin B.F., Peng X.S. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother. Pharmacol. 2011, 68:1027-1032.
5. Zhu L.P., Xing J., Wang Q.X., Kou L., Li C., Hu B., Wu Z.W., Wang J.J., Xu G.X. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur. J. Pharmacol. 2009, 617:23-27.
6. Jiang L.P., Zou C., Yuan X., Luo W., Wen Y., Chen Y. N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol. Appl. Biochem. 2009, 54:113-120.
7. Song H.F., Liu X.W., Zhang H.N., Zhu B.Z., Yuan S.J., Liu S.Y., Tang Z.M. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta. Pharmacol. Sin. 2005, 26:124-128.
8. Sim B.K., Fogler W.E., Zhou X.H., Liang H., Madsen J.W., Luu K., O'Reilly M.S., Tomaszewski J.E., Fortier A.H. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999, 3:41-51.
9. Thomas J.P., Arzoomanian R.Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2003, 21:223-231.
10. Grohganz H., Rischer M., Brandl M. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal. Chem. 2008, 80:1290-1296.
11. Heinig K., Wirz T. Determination of taspoglutide in human and animal plasma using liquid chromatography-tandem mass spectrometry with orthogonal column-switching. Anal. Chem. 2009, 81:3705-3713.
12. Oswald T., Rinas U. Chloramphenicol resistance interferes with purification of histidine-tagged fusion proteins from recombinant Escherichia coli. Anal. Biochem. 1996, 236:357-358.
13. Noronha S., Kaufman J., Shiloach J. Use of streamline chelating for capture and purification of poly-His-tagged recombinant proteins. Bioseparation 1999, 8:145-151.
14. Grohganz H., Rischer M., Brandl M. Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. Eur. J. Pharm. Sci. 2004, 21:191-196.
15. van Platerink C.J., Janssen H.G., Horsten R., Haverkamp J. Quantification of ACE inhibiting peptides in human plasma using high performance liquid chromatography-mass spectrometry. J. Chromatogr. B 2006, 830:151-157.
16. Li H.L., Li S., Shao J.Y., Lin X.B., et al. Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. Gene Ther. 2008, 15:247-256.
17. Wolf R., Rosche F., Hoffmann T., Demuth H.U. Immunoprecipitation and liquid chromatographic-mass spectrometric determination of the peptide glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 from human plasma samples. J. Chromatogr. A 2001, 926:21-27.